VVOS
Vivos Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Devices
$0.41-1.98%
Price as of Jul 20, 2026
VVOS growth
Vivos Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +33.8%
- EBITDA
- —
- EBIT
- -99.9%
- EPS
- -19.2%
- Free cash flow
- -29.4%
- Operating cash flow
- -25.1%
Forward estimates
- Revenue
- -26.7%
- EBITDA
- +44.4%
- EPS
- +70.7%
Three-year CAGR
- Revenue
- +2.9%
- EBITDA
- -88.7%
- EBIT
- -78.1%
- Net income
- -90.6%
- EPS
- +7.2%
- Free cash flow
- -32.8%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.